drugset / Trial / NCT00457964
RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
Phase 1/2
Completed
36 enrolled
Children's Hospital Medical Center, Cincinnati
Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to find out what effects RAD001 has on angiomyolipomas of a person with Tuberous Sclerosis Complex and to determine the safe dose of RAD001 without toxicity. The hypothesis is that the drug will inhibit the growth of the angiomyolipomas and possibly even cause regression.
Timeline
- Start
- 2005-08
- Primary completion
- 2013-07
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg | — |
| Subject | Everolimus | Small molecule | 10 mg | — |
| Subject | Everolimus | Small molecule | 30 mg | — |
| Subject | Everolimus | Small molecule | 50 mg | — |
| Subject | Everolimus | Small molecule | 70 mg | — |